The Securities and Exchange Commission has announced that it has resolved civil FCPA charges against the French drug company, Sanofi, and its Kazakh and Middle Eastern subsidiaries. The company will pay $25 million to settle allegations that it participated in bribery schemes to secure government tenders and increase prescriptions.
September 4, 2018
Pharmaceutical giant charged with bribery
Related by Topic
New Post
McKinsey’s South African subsidiary resolves FCPA investigation
December 17, 2024
News Alert
BIT Mining settles with DOJ and SEC to resolve FCPA violations, while former CEO faces bribery-related charges
November 21, 2024
News Alert
Son of former Comptroller General of Ecuador pleads guilty in Odebrecht bribery scandal
November 19, 2024
News Alert